Imugene (ASX:IMU) Research & Development : A$62.89 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Imugene's Research & Development for the six months ended in Dec. 2023 was A$44.68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$62.89 Mil.

Imugene Research & Development Historical Data

The historical data trend for Imugene's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Research & Development Chart

Imugene Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Research & Development

Get a 7-Day Free Trial

7.61

9.36

15.36

36.61

30.87

Imugene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															13.83	22.78	12.65	18.21	44.68

Imugene Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$62.89 Mil.

Imugene (ASX:IMU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Imugene Research & Development Related Terms

Thank you for viewing the detailed overview of Imugene's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene (ASX:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

IUGNF:USA

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines